ClinicalTrials.Veeva

Menu

Irisin Hormone Levels in Endometrial Hyperplasia

K

Kayseri Education and Research Hospital

Status

Unknown

Conditions

Endometrial Hyperplasia

Study type

Observational

Funder types

Other

Identifiers

NCT02903797
2016/466

Details and patient eligibility

About

The purpose of the study is to determine serum irisin hormone levels an its relation between endometrial hyperplasia

Full description

The study consisted of two groups. The first group was formed of the patients diagnosed endometrial hyperplasia histopathologically , and the controls were healthy women admitted to the clinic just for annual examination without any complain and symptoms. Patients in the 35-50 age range in both groups were included in the study. The histopathologic diagnosis of patients was established for Kayseri Education and Research Hospital Pathology clinics. Demographic parameters such as age, menopausal status, body mass index (BMI), body weight and known familial cancer story were registered.

Pregnancy, liver function disorders, cardiovascular disease, metabolic disease, diabetes, chronic kidney disease, central nerves system disease, immunosuppressive drug use, another known malignancy and excessive exercises in among one month were all exclusion criteria for the patients.

3 cc peripheral venous blood samples were taken in the patients' diagnosed endometrial hyperplasia in the course of evaluation the biopsy results and in controls during their examinations just for only once. Blood samples were centrifuged in 3200 rpm speed for 10 minutes, and stored in -80 'C until the analysis. Blood samples were evaluated on the same day after four mounts for stored first blood sample. Serum Irisin levels were evaluated with enzyme- linked immunosorbent assays kit (Catalog number: K4761-100 Biovision USA) in Kayseri Research and Education Hospital Biochemical Clinics.

Enrollment

80 estimated patients

Sex

Female

Ages

35 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • between 35-50 years of age
  • İn endometrial hyperplasia group; patients who were diagnosed endometrial hyperplasia histopathologically

Exclusion criteria

  • Pregnancy
  • Liver function disorders
  • Cardiovascular disease
  • Metabolic disease
  • Diabetes
  • Chronic kidney disease
  • Central nerves system disease
  • Immunosuppressive drug use
  • Another known malignancy
  • Excessive exercises in among one month

Trial design

80 participants in 2 patient groups

Endometrial Hyperplasia
Description:
The first group was formed of the patients diagnosed endometrial hyperplasia histopathologically
Control group
Description:
The control group was formed of the patients who were healthy women admitted to the clinic just for annual examination without any complain and symptoms

Trial contacts and locations

1

Loading...

Central trial contact

Erdem SAHİN, Principal İnvestigator; Yusuf MADENDAG, Contact Backup

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems